Utama › Penyakit Pencernaan › Tennessee
Kajian klinikal Penyakit Pencernaan di Tennessee
6 kajian untuk Penyakit Pencernaan sedang mencari peserta di lokasi di Tennessee.
Bandar di Tennessee
Teks kajian rasmi (Bahasa Inggeris)
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
- Vanderbilt University Medical Center, Nashville
Mengambil pesertaFasa 3
Umur 18 hingga 90 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07197944Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07222800Product Surveillance Registry
- Germantown
- Memphis
- Nashville
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Sep 2026 · NCT01524276A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Chattanooga
- 89bio Clinical Study Site, Cordova
- 89bio Clinical Study Site, Hermitage
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Cordova
- 89bio Clinical Study Site, Hermitage
- 89bio Clinical Study Site, Nashville
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06419374Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).
- St. Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 1
Sehingga umur 22 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT05664113Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.